Results 151 to 160 of about 160,832 (337)

Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio‐Oncology

European Journal of Heart Failure, EarlyView.
Specific characteristics of HFpEF universal definition in cancer patients. Abstract Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized in cancer patients and survivors, yet it remains underdiagnosed and its epidemiology largely unknown.
Kalliopi Keramida, Teresa Lopez‐Fernandez, Markus S. Anker, Mark C. Petrie, Pietro Ameri, Lisa J. Anderson, Jutta Bergler‐Klein, Anita Deswal, Dimitrios Farmakis, Borja Ibañez, Carolyn S.P. Lam, Ninian N. Lang, Alexander R. Lyon, Mariana Mirabel, Brenda Moura, Walter J. Paulus, Amina Rakisheva, Gianluigi Savarese, Michele Senni, Carlo Gabriele Tocchetti, Marco Metra, Gerasimos Filippatos   +21 more
wiley   +1 more source

Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells

, 2015
Takaaki Miyake, Yoshio Honma, Takeshi Urano, Nobuo Kato, Junji Suzumiya   +4 more
openalex   +2 more sources

Natural Products Targeting Notch Signaling in Cancer: Mechanistic Insights and Food‐Based Chemoprevention Potential

Food Frontiers, EarlyView.
The Notch signaling pathway plays a dual role in cancer, acting as both a tumor promoter and suppressor depending on cellular context. This review highlights how natural products modulate Notch signaling to inhibit tumor initiation, progression, angiogenesis, and cancer stem cell maintenance.
Rabab Fatima, Parteek Prasher, Mousmee Sharma, Dietrich Büsselberg, Gabriela Figueroa‐González, Octavio Daniel Reyes‐Hernández, Edgar Yebrán Villegas‐Vázquez, Hernán Cortés, Gerardo Leyva‐Gómez, Jesús Herrera‐Bravo, Solomon Habtemariam, Javad Sharifi‐Rad, Monica Butnariu, Cristian Berar, Angela Caunii, William C. Cho   +15 more
wiley   +1 more source

Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model

, 2015
Bonnie L. Hylander, Arindam Sen, Sarah H. Beachy, Rose Pitoniak, Soumya Ullas, John F. Gibbs, Jingxin Qiu, Joshua Prey, Gerald J. Fetterly, Elizabeth A. Repasky   +9 more
openalex   +1 more source

Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer [PDF]

, 2019
Liming Sheng, Xiaoying Cui, Lei Cheng, Ying Chen, Xianghui Du   +4 more
openalex   +1 more source

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial [PDF]

, 2022
Samuel A. Funt, Michael Lattanzi, Karissa Whiting, Hikmat Al‐Ahmadie, Colleen Quinlan, Min Yuen Teo, Chung‐Han Lee, David H. Aggen, Danielle Elise Zimmerman, Deaglan Joseph McHugh, Arlyn Apollo, Trey Durdin, Hong Truong, Jeffrey M. Kamradt, Maged Khalil, Bradley W. Lash, Irina Ostrovnaya, Asia S. McCoy, Grace Hettich, Ashley Marie Regazzi, Marwah Jihad, Neha Ratna, Abigail Boswell, Kaitlyn Francese, Yuanquan Yang, Edmund Folefac, Harry W. Herr, S. Machele Donat, Eugene J. Pietzak, K. Eugene, Timothy F. Donahue, Alvin C. Goh, William C. Huang, Dean F. Bajorin, Gopa Iyer, Bernard H. Bochner, Arjun Vasant Balar, Amir Mortazavi, Jonathan E. Rosenberg   +38 more
openalex   +1 more source

Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer

Cell Death Discovery
TP53 mutations are recognized to correlate with a worse prognosis in individuals with non-small cell lung cancer (NSCLC). There exists an immediate necessity to pinpoint selective treatment for patients carrying TP53 mutations.
Yen-Han Tseng, Trieu Thi My Tran, Jinghua Tsai Chang, Yu-Tang Huang, Anh Thuc Nguyen, Ian Yi‑Feng Chang, Yi-Tung Chen, Hao-Wen Hsieh, Yue-Li Juang, Peter Mu-Hsin Chang, Tzu-Yi Huang, Ying-Chih Chang, Yuh-Min Chen, Hsuan Liu, Chi-Ying F. Huang   +14 more
doaj   +1 more source

Gemcitabine and docetaxel in a patient with primary ovarian leiomyosarcoma: a case report and review of literature [PDF]

, 2017
Yoko Furutake, Tomoyuki Fukagawa, Yasuko Suga, Takayuki Nagasawa, Seiya Sato, Hideo Omi, Masahiro Kagabu, Atsumi Chiba, Tadahiro Shoji, Satoshi Takeuchi, Tamotsu Sugai, Hiroaki Itamochi, Toru Sugiyama   +12 more
openalex   +1 more source

Interferon-bèta Enhances Sensitivity to Gemcitabine in Pancreatic Cancer [PDF]

, 2020
Amber Blaauboer, Stephanie Booy, Peter M. van Koetsveld, Bas Karels, Fadime Dogan, Suzanne van Zwienen, Casper H.J. van Eijck, Leo J. Hofland   +7 more
openalex   +1 more source

Cell‐Penetrating Poly(disulfide)s

Helvetica Chimica Acta, EarlyView.
The first 10 years of cell‐penetrating poly(disulfide)s (CPDs) are reviewed comprehensively. CPDs are prepared by ring‐opening polymerization of cyclic disulfides. The many sidechain structures and diverse biological applications realized so far beyond the original arginines identify CPDs as the most popular current delivery system that operates with ...
Michael Cognet, Giacomo Renno, Nicholas Rose, Yuheng Zhang, Pierre Josso, Julia Moreno, Xudong Ren, Jules Bouffard, Saidbakhrom Saidjalolov, Naomi Sakai, Stefan Matile   +10 more
wiley   +1 more source